Activated phosphoinositide 3‐dinase delta syndrome (APDS): An update
Authors:
- Vassilios LougarisVLVassilios Lougaris
- Caterina CancriniCCCaterina Cancrini
- Beatrice RivaltaBRBeatrice Rivalta
- Riccardo CastagnoliRiccardo Castagnoli
- Giuliana GiardinoGGGiuliana Giardino
- Stefano VolpiSVStefano Volpi
- Lucia LeonardiLLLucia Leonardi
- Francesco La TorreFrancesco La Torre
- Silvia FedericiSFSilvia Federici
- Bianca Laura CinicolaBCBianca Laura Cinicola
Open Access
- 25 January 2022
- journal article
- research article
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 33 (S27) , 69-72
Abstract
Activated phosphoinositide 3-kinase delta syndrome (APDS) is a recently described form of inborn error of immunity (IEI) caused by heterozygous mutations in PIK3CD or PIK3R1 genes, respectively, encoding leukocyte-restricted catalytic p110δ subunit and the ubiquitously expressed regulatory p85 α subunit of the phosphoinositide 3-kinase δ (PI3Kδ). The first described patients with respiratory infections, hypogammaglobulinemia with normal to elevated IgM serum levels, lymphopenia, and lymphoproliferation. Since the original description, it is becoming evident that the onset of disease may be somewhat variable over time, both in terms of age at presentation and in terms of clinical and immunological complications. In many cases, patients are referred to various specialists such as hematologists, rheumatologists, gastroenterologists, and others, before an immunological evaluation is performed, leading to delay in diagnosis, which negatively affects their prognosis. The significant heterogeneity in the clinical and immunological features affecting APDS patients requires awareness among clinicians since good results with p110δ inhibitors have been reported, certainly ameliorating these patients’ quality of life and prognosis.Keywords
This publication has 11 references indexed in Scilit:
- Increased activation of PI3 kinase-δ predisposes to B-cell lymphomaBlood, 2020
- Activating mutations in PIK3CD disrupt the differentiation and function of human and murine CD4+ T cellsJournal of Allergy and Clinical Immunology, 2019
- Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome RegistryFrontiers in Immunology, 2018
- Absence of Tumor Necrosis Factor Supports Alternative Activation of Macrophages in the Liver after Infection with Leishmania majorFrontiers in Immunology, 2018
- Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort studyJournal of Allergy and Clinical Immunology, 2017
- Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort studyJournal of Allergy and Clinical Immunology, 2016
- Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3KJournal of Experimental Medicine, 2014
- A human immunodeficiency caused by mutations in the PIK3R1 geneJournal of Clinical Investigation, 2014
- Phosphoinositide 3-Kinase δ Gene Mutation Predisposes to Respiratory Infection and Airway DamageScience, 2013
- Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiencyNature Immunology, 2013